Novo Nordisk says Wegovy approved in China for liver disease MASH
5 Articles
5 Articles
Novo Nordisk says Wegovy approved in China for liver disease MASH - Regional Media News
STOCKHOLM, Sept 10 (Reuters) - Denmark's Novo Nordisk said on Thursday its blockbuster weight-loss drug Wegovy had been approved in China as the first GLP-1 RA class of drugs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). "The liver health-related benefits evidence extends the established [...]
Novo Nordisk says Wegovy approved in China for liver disease MASH
STOCKHOLM, Sept 10 (Reuters) - Denmark's Novo Nordisk said on Thursday its blockbuster weight-loss drug Wegovy had been approved in China as the first GLP-1 RA class of drugs for the treatment of metabolic dysfunction-associated steatohepatitis ...
The Danish pharmaceutical company Novo Nordisk has extended in China another important approval for its weight loss medication Wegovy The post China Wegovy approval for the treatment of fatty liver first appeared on Nordisch.info.
It thus becomes the first and only GLP-1 receptor agonist indicated for the treatment of the pathology
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
